Year: 2021

SpringWorks Therapeutics Announces Dosing of First Patient in Phase 1b/2 Trial Evaluating Nirogacestat in Combination with Elranatamab (PF-06863135) in Patients with Relapsed or Refractory Multiple Myeloma

Written by Customer Service on December 6, 2021. Posted in Public Companies.

STAMFORD, Conn., Dec. 06, 2021 (GLOBE NEWSWIRE) — SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that the first patient has been dosed in a Phase 1b/2 trial evaluating nirogacestat, SpringWorks’ investigational gamma secretase inhibitor (GSI), in combination with elranatamab (PF-06863135) Pfizer’s investigational B-cell maturation antigen (BCMA) CD3-targeted bispecific antibody, in patients with relapsed or refractory multiple myeloma. Gamma secretase inhibition prevents the cleavage and shedding of BCMA from the surface of myeloma cells. In preclinical models, nirogacestat has been shown to increase the cell surface density of BCMA and reduce levels of soluble BCMA, thereby...

Adagene Presents Clinical Data Demonstrating Strong Safety and Early Signals of Efficacy in Treatment-Resistant Tumors for Anti-CTLA-4 Monoclonal Antibody, ADG116, at ESMO-IO 2021

Written by Customer Service on December 6, 2021. Posted in Public Companies.

– Additional highlights include pharmacodynamic biomarker analyses from ongoing trial of anti-CD137 antibody, ADG106, in combination with anti-PD-1 toripalimab – SAN DIEGO and SUZHOU, China, Dec. 06, 2021 (GLOBE NEWSWIRE) — Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based immunotherapies, today announced clinical data on its anti-CTLA-4 monoclonal antibody, ADG116, and anti-CD137 agonist, ADG106, in two poster presentations at the European Society for Medical Oncology Immuno-Oncology (ESMO-IO) Congress 2021, to be held virtually and in Geneva, Switzerland from December 8 to 11, 2021. Both posters are available in the Publications section of the company’s website at www.adagene.com. In the...

Bolt Biotherapeutics Reports Interim BDC-1001 Phase 1/2 Data Demonstrating a Safe and Well-tolerated Profile and Emerging Clinical Activity at the ESMO Immuno-Oncology Congress 2021

Written by Customer Service on December 6, 2021. Posted in Public Companies.

Company to continue monotherapy dose-escalation and evaluate weekly dose regimen Combination dose-escalation study of BDC-1001 with Opdivo® on target to initiate by year end 2021 Live conference call and webcast today at 8:00 a.m. ET/5:00 a.m. PT REDWOOD CITY, Calif., Dec. 06, 2021 (GLOBE NEWSWIRE) — Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune systems, today announced the presentation of interim clinical data from the company’s ongoing Phase 1/2 study of BDC-1001, the company’s lead immune-stimulating antibody conjugate (ISAC) in a poster session at the European Society for Medical Oncology Immuno-Oncology (ESMO I-O) Congress 2021, being held...

Liberty Gold Completes 2021 Resource Upgrade Drilling in the Discovery Zone, Black Pine, Idaho

Written by Customer Service on December 6, 2021. Posted in Public Companies.

LBP380: 1.52 g/t Au over 30.5 m and 2.44 g/t Au over 21.3 mLBP393: 0.56 g/t Au over 64.0 m including 0.89 g/t Au over 33.5 m VANCOUVER, British Columbia, Dec. 06, 2021 (GLOBE NEWSWIRE) — Liberty Gold Corp. (TSX: LGD; OTCQX: LGDTF) (“Liberty Gold” or the “Company”) is pleased to announce that the 2021 reverse circulation (“RC”) drilling campaign in the Discovery Zone (“DZ”) at the Black Pine Oxide Gold Deposit (“Black Pine”) was completed at the end of November. The objective of the program is to upgrade inferred resources to indicated to be included in a future prefeasibility study. Assay results confirm the continuity of stacked moderate to high-grade zones of DZ gold mineralization and support or exceed expectations within the targeted inferred blocks. Currently, the DZ represents 78% of the indicated resource and 52% of the...

Puma Exploration Completes Property-Scale Airborne Radiometric Survey

Written by Customer Service on December 6, 2021. Posted in Public Companies.

Figure 1: Heliborne Radiometric Survey in Progress at Williams BrookHeliborne Radiometric Survey in Progress at Williams BrookFigure 2: Detailed Flight Path for the Entire Williams Brook Heliborne Geophysical SurveyDetailed Flight Path for the Entire Williams Brook Heliborne Geophysical SurveyRIMOUSKI, Quebec, Dec. 06, 2021 (GLOBE NEWSWIRE) — Puma Exploration Inc. (TSXV: PUMA) (the “Company” or “Puma”) is pleased to announce that it has completed a 2,185 line-km airborne radiometric survey that covers the entirety of its 20,000 ha Williams Brook Property in New Brunswick, Atlantic-Canada. The radiometric survey will help identify potassic alteration and potential associated gold mineralisation across the property. Figure 1: Heliborne Radiometric Survey in Progress at Williams Brook accompanying...

Grapefruit USA, Inc. (OTCQB: GPFT) Leverages Its Patented Time Release Technology to Roll Out the World’s Most Effectively Bioavailable CBD Delivery Cream

Written by Customer Service on December 6, 2021. Posted in Public Companies.

LOS ANGELES and DESERT HOT SPRINGS, Calif., Dec. 06, 2021 (GLOBE NEWSWIRE) — via InvestorWire – Grapefruit USA, Inc. (OTCQB: GPFT) (“Grapefruit” or the “Company”), a premiere California-based cannabis and hemp company, today announces the official launch of the world’s first patented time-release, hemp-based CBD topical cream with boosted bioavailability, made possible by its proprietary Hourglass™ technology. Hourglass™ is a unique method for staggered and discreet topical delivery of CBD. The brand-new technology, developed by Grapefruit, leverages a proprietary process that involves the grinding of CBD into nano sized particles, substantially smaller than the width of a human hair, which allows for significantly higher bioavailability and absorption. The nano-particle technology enables anyone who wants to enjoy the incredible...

TELUS maintains our decade-long leadership position with fewest complaints amongst national carriers

Written by Customer Service on December 6, 2021. Posted in Public Companies.

Our commitment to put customers first has earned us the most loyal customer base in the industry VANCOUVER, British Columbia, Dec. 06, 2021 (GLOBE NEWSWIRE) — For more than a decade, TELUS has led the industry with the fewest complaints amongst national carriers as confirmed by this year’s Commission for Complaints about Telecom-Television Services (CCTS) report. We are proud to once again differentiate ourselves from our peers on this important metric which demonstrates our commitment to putting our customers first, embracing their feedback to continually improve, and our never-ending quest to provide our customers with the best and most innovative technologies that improve their daily lives. “The significant investments we make in our culture of putting customers first and our superior network has earned us the most loyal customer...

GCP Applied Technologies Signs a Definitive Agreement to Be Acquired by Saint-Gobain

Written by Customer Service on December 6, 2021. Posted in Mergers And Acquisitions.

ALPHARETTA, Ga., Dec. 06, 2021 (GLOBE NEWSWIRE) — GCP Applied Technologies Inc. (NYSE: GCP) (GCP or the Company), today announced that it has entered into a definitive agreement pursuant to which Saint-Gobain will acquire all of the outstanding shares of GCP Applied Technologies for $32.00 per share, in cash, in a transaction valued at approximately $2.3 billion (approximately €2.0 billion). The agreed upon price represents a premium of 39% above the volume-weighted average price per GCP share for the 30-trading days ended on the undisturbed date of November 30, 2021. The business combination has been unanimously approved by the Boards of Directors of Saint-Gobain and GCP Applied Technologies respectively. Saint-Gobain has obtained undertakings from Starboard and Standard Investments (formerly known as 40 North) / Standard Industries...

Amendment: Boussard & Gavaudan Investment Management LLP: Form 8.3 – Playtech Plc

Written by Customer Service on December 6, 2021. Posted in Mergers And Acquisitions.

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Boussard & Gavaudan Investment Management LLP Boussard & Gavaudan Asset Management LP Boussard & Gavaudan Gestion SAS acting on behalf of various funds(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. (c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree Playtech Plc(d) If an...

Aesthetic Medical International Announces Business Updates on Newly-acquired Non-surgical Business in Guangzhou

Written by Customer Service on December 6, 2021. Posted in Mergers And Acquisitions.

SHENZHEN, China, Dec. 06, 2021 (GLOBE NEWSWIRE) — Aesthetic Medical International Holdings Group Limited (Nasdaq: AIH) (the “Company” or “AIH”), a leading provider of aesthetic medical services in China, today announced the operational updates on its newly-acquired non-surgical satellite clinic in Guangzhou. To further leverage the Company’s extensive operational experiences and resources in the Guangdong-Hong Kong-Macao Greater Bay Area, Guangzhou Pengai Aesthetic Medical Hospital Co., Ltd., a wholly-owned subsidy of the Company, entered into a definitive equity transfer agreement (the “Agreement”) with a shareholder of Guangzhou Meixi Aesthetic Medical Clinic Company Limited (“Meixi”) on October 17, 2021. Pursuant to the Agreement, the Company purchased 73% of equity interests in Meixi from its existing shareholder. Meixi’s name...

Year: 2021

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals